glp 1 fda ban Novo pressures GLP-1 compounders as FDA ban takes hold

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

20.63

★★★★☆4.8 (126)

FDA Proposes Ban on Bulk Compounding for Semaglutide, Tirzepatide, and Liraglutide

29.57

★★★★★4.9 (98)

The New York Times spotlighted MEDVi. The FDA had already warned the self-proclaimed 'fastest growing company in history.'

25.35

★★★★★5.0 (157)

FDA takes aim at telehealth companies for promoting unofficial weight loss drug dupes

23.05

★★★★★4.7 (84)

The Last - The FDA's decision to ban non-FDA-approved GLP-1 active ingredients threatens to disrupt the business models of telehealth companies that offer affordable weight-loss treatments. >> Link 👇

29.66

★★★★★4.9 (203)

Compass Point's Max Reale talks the impact of a possible FDA ban on compounded GLP-1 offerings

24.05

★★★★★5.0 (176)

FDA moves to remove GLP-1 medications from 503B Bulks List

24.82

★★★★★4.8 (132)